Fatal cardiac and renal allograft rejection with lenalidomide therapy for light-chain amyloidosis. Academic Article uri icon

Overview

abstract

  • We describe a patient who underwent a successful heart and kidney transplant for light-chain amyloidosis. She had an excellent hematologic response to bortezomib/dexamethasone therapy. Follow-up therapy with lenalidomide was started, and the patient quickly had a fatal allograft rejection of the heart and kidney. We present evidence to support the theory that lenalidomide, a known immunomodulator, may have stimulated the immune system and precipitated the fatal rejection episode.

publication date

  • August 5, 2013

Research

keywords

  • Amyloidosis
  • Graft Rejection
  • Heart Transplantation
  • Immunologic Factors
  • Kidney Transplantation
  • Thalidomide

Identity

Scopus Document Identifier

  • 84884905611

Digital Object Identifier (DOI)

  • 10.1111/ajt.12391

PubMed ID

  • 23914832

Additional Document Info

volume

  • 13

issue

  • 10